Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy

Terpos, E. (Evangelos)|||/items/f7dbaa50-9ab3-42ba-bf5a-d80977a9f8d4; Kostopoulos, I.V. (Ioannis V.)|||/items/5854daeb-2a43-4bab-b52b-2ee713b04344; Kastritis, E. (Efstathios)|||/items/6f26f927-536f-4cab-ae12-8f9ef542619d; Ntanasis-Stathopoulos, I. (Ioannis)|||/items/81f85249-34c0-4f57-99d7-80c26718f555; Migkou, M. (Magdalini)|||/items/39eca5c7-6f53-488f-a7ca-239a8d8cd00f; Rousakis, P. (Pantelis)|||/items/4091ddbe-f888-4d04-beba-e7998b8ef7d7; Argyriou, A.T. (Alexandra T.)|||/items/b0888fea-4179-415e-b360-57a62744b956; Kanellias, N. (Nikolaos)|||/items/44c10986-4182-4083-b632-8d7bc7a742ee; Fotiou, D. (Despina)|||/items/483113f5-569e-4a11-ae14-0fa71c306dc8; Eleutherakis-Papaiakovou, E. (Evangelos)|||/items/19bda14d-006a-4571-9066-a89417da6ef8; Gavriatopoulou, M. (Maria)|||/items/c2f76c5c-2312-417f-8ab0-b0dbe4b76f2e; Ziogas, D.C. (Dimitrios C.)|||/items/7af8e18b-60c6-4f06-a041-8c544477fdda; Papanota, A.M. (Aristea-Maria)|||/items/77c9cf83-fe4d-4373-bed4-fd640ebbd3f2; Spyropoulou-Vlachou, M. (Marilyn)|||/items/d94a63b1-7b9e-40f6-87ec-d899e159b37f; Trougakos, I.P. (Ioannis P.)|||/items/85ec9dc3-b435-4713-ad0b-1e502f61726c; Tsitsilonis, O.E. (Ourania E.)|||/items/375815ec-1178-45ab-b55a-6277eba9ddc3; Paiva, B. (Bruno)|||/items/b2c3efc5-27e1-4425-b452-efba1522c1d5; Dimopoulos, M.A. (Meletios A.)|||/items/15a77e11-69c3-44a2-8476-eb93bbe8cc0e

Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy

Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10−5; 17% at 10−6. All patients...

Descripción completa

Detalles Bibliográficos
Autores:	Terpos, E. (Evangelos)\|\|\|/items/f7dbaa50-9ab3-42ba-bf5a-d80977a9f8d4, Kostopoulos, I.V. (Ioannis V.)\|\|\|/items/5854daeb-2a43-4bab-b52b-2ee713b04344, Kastritis, E. (Efstathios)\|\|\|/items/6f26f927-536f-4cab-ae12-8f9ef542619d, Ntanasis-Stathopoulos, I. (Ioannis)\|\|\|/items/81f85249-34c0-4f57-99d7-80c26718f555, Migkou, M. (Magdalini)\|\|\|/items/39eca5c7-6f53-488f-a7ca-239a8d8cd00f, Rousakis, P. (Pantelis)\|\|\|/items/4091ddbe-f888-4d04-beba-e7998b8ef7d7, Argyriou, A.T. (Alexandra T.)\|\|\|/items/b0888fea-4179-415e-b360-57a62744b956, Kanellias, N. (Nikolaos)\|\|\|/items/44c10986-4182-4083-b632-8d7bc7a742ee, Fotiou, D. (Despina)\|\|\|/items/483113f5-569e-4a11-ae14-0fa71c306dc8, Eleutherakis-Papaiakovou, E. (Evangelos)\|\|\|/items/19bda14d-006a-4571-9066-a89417da6ef8, Gavriatopoulou, M. (Maria)\|\|\|/items/c2f76c5c-2312-417f-8ab0-b0dbe4b76f2e, Ziogas, D.C. (Dimitrios C.)\|\|\|/items/7af8e18b-60c6-4f06-a041-8c544477fdda, Papanota, A.M. (Aristea-Maria)\|\|\|/items/77c9cf83-fe4d-4373-bed4-fd640ebbd3f2, Spyropoulou-Vlachou, M. (Marilyn)\|\|\|/items/d94a63b1-7b9e-40f6-87ec-d899e159b37f, Trougakos, I.P. (Ioannis P.)\|\|\|/items/85ec9dc3-b435-4713-ad0b-1e502f61726c, Tsitsilonis, O.E. (Ourania E.)\|\|\|/items/375815ec-1178-45ab-b55a-6277eba9ddc3, Paiva, B. (Bruno)\|\|\|/items/b2c3efc5-27e1-4425-b452-efba1522c1d5, Dimopoulos, M.A. (Meletios A.)\|\|\|/items/15a77e11-69c3-44a2-8476-eb93bbe8cc0e
Tipo de recurso:	artículo
Fecha de publicación:	2019
País:	España
Institución:	Universidad de Navarra
Repositorio:	Dadun. Depósito Académico Digital de la Universidad de Navarra
Idioma:	inglés
OAI Identifier:	oai:dadun.unav.edu:10171/62276
Acceso en línea:	https://hdl.handle.net/10171/62276
Access Level:	acceso abierto
Palabra clave:	Minimal residual disease (MRD) Phenotypic profiles Suitable method Next-generation flow (NGF)

id	ES_7c0692c9d71ed368337ba2a8a35d0e30
oai_identifier_str	oai:dadun.unav.edu:10171/62276
network_acronym_str	ES
network_name_str	España
repository_id_str
spelling	Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapyTerpos, E. (Evangelos)\|\|\|/items/f7dbaa50-9ab3-42ba-bf5a-d80977a9f8d4Kostopoulos, I.V. (Ioannis V.)\|\|\|/items/5854daeb-2a43-4bab-b52b-2ee713b04344Kastritis, E. (Efstathios)\|\|\|/items/6f26f927-536f-4cab-ae12-8f9ef542619dNtanasis-Stathopoulos, I. (Ioannis)\|\|\|/items/81f85249-34c0-4f57-99d7-80c26718f555Migkou, M. (Magdalini)\|\|\|/items/39eca5c7-6f53-488f-a7ca-239a8d8cd00fRousakis, P. (Pantelis)\|\|\|/items/4091ddbe-f888-4d04-beba-e7998b8ef7d7Argyriou, A.T. (Alexandra T.)\|\|\|/items/b0888fea-4179-415e-b360-57a62744b956Kanellias, N. (Nikolaos)\|\|\|/items/44c10986-4182-4083-b632-8d7bc7a742eeFotiou, D. (Despina)\|\|\|/items/483113f5-569e-4a11-ae14-0fa71c306dc8Eleutherakis-Papaiakovou, E. (Evangelos)\|\|\|/items/19bda14d-006a-4571-9066-a89417da6ef8Gavriatopoulou, M. (Maria)\|\|\|/items/c2f76c5c-2312-417f-8ab0-b0dbe4b76f2eZiogas, D.C. (Dimitrios C.)\|\|\|/items/7af8e18b-60c6-4f06-a041-8c544477fddaPapanota, A.M. (Aristea-Maria)\|\|\|/items/77c9cf83-fe4d-4373-bed4-fd640ebbd3f2Spyropoulou-Vlachou, M. (Marilyn)\|\|\|/items/d94a63b1-7b9e-40f6-87ec-d899e159b37fTrougakos, I.P. (Ioannis P.)\|\|\|/items/85ec9dc3-b435-4713-ad0b-1e502f61726cTsitsilonis, O.E. (Ourania E.)\|\|\|/items/375815ec-1178-45ab-b55a-6277eba9ddc3Paiva, B. (Bruno)\|\|\|/items/b2c3efc5-27e1-4425-b452-efba1522c1d5Dimopoulos, M.A. (Meletios A.)\|\|\|/items/15a77e11-69c3-44a2-8476-eb93bbe8cc0eMinimal residual disease (MRD)Phenotypic profilesSuitable methodNext-generation flow (NGF)Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10−5; 17% at 10−6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts’ and tumor-associated monocytes/macrophages’ predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10−6.Ovid Technologies (Wolters Kluwer Health)Dadun. Depósito Académico Digital Universidad de Navarra20212021-10-2620192019-01-0120192019-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10171/62276reponame:Dadun. Depósito Académico Digital de la Universidad de Navarrainstname:Universidad de NavarraInglésengopen accesshttp://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccessoai:dadun.unav.edu:10171/622762026-06-21T12:47:57Z
dc.title.none.fl_str_mv	Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy
title	Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy
spellingShingle	Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy Terpos, E. (Evangelos)\|\|\|/items/f7dbaa50-9ab3-42ba-bf5a-d80977a9f8d4 Minimal residual disease (MRD) Phenotypic profiles Suitable method Next-generation flow (NGF)
title_short	Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy
title_full	Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy
title_fullStr	Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy
title_full_unstemmed	Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy
title_sort	Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy
dc.creator.none.fl_str_mv	Terpos, E. (Evangelos)\|\|\|/items/f7dbaa50-9ab3-42ba-bf5a-d80977a9f8d4 Kostopoulos, I.V. (Ioannis V.)\|\|\|/items/5854daeb-2a43-4bab-b52b-2ee713b04344 Kastritis, E. (Efstathios)\|\|\|/items/6f26f927-536f-4cab-ae12-8f9ef542619d Ntanasis-Stathopoulos, I. (Ioannis)\|\|\|/items/81f85249-34c0-4f57-99d7-80c26718f555 Migkou, M. (Magdalini)\|\|\|/items/39eca5c7-6f53-488f-a7ca-239a8d8cd00f Rousakis, P. (Pantelis)\|\|\|/items/4091ddbe-f888-4d04-beba-e7998b8ef7d7 Argyriou, A.T. (Alexandra T.)\|\|\|/items/b0888fea-4179-415e-b360-57a62744b956 Kanellias, N. (Nikolaos)\|\|\|/items/44c10986-4182-4083-b632-8d7bc7a742ee Fotiou, D. (Despina)\|\|\|/items/483113f5-569e-4a11-ae14-0fa71c306dc8 Eleutherakis-Papaiakovou, E. (Evangelos)\|\|\|/items/19bda14d-006a-4571-9066-a89417da6ef8 Gavriatopoulou, M. (Maria)\|\|\|/items/c2f76c5c-2312-417f-8ab0-b0dbe4b76f2e Ziogas, D.C. (Dimitrios C.)\|\|\|/items/7af8e18b-60c6-4f06-a041-8c544477fdda Papanota, A.M. (Aristea-Maria)\|\|\|/items/77c9cf83-fe4d-4373-bed4-fd640ebbd3f2 Spyropoulou-Vlachou, M. (Marilyn)\|\|\|/items/d94a63b1-7b9e-40f6-87ec-d899e159b37f Trougakos, I.P. (Ioannis P.)\|\|\|/items/85ec9dc3-b435-4713-ad0b-1e502f61726c Tsitsilonis, O.E. (Ourania E.)\|\|\|/items/375815ec-1178-45ab-b55a-6277eba9ddc3 Paiva, B. (Bruno)\|\|\|/items/b2c3efc5-27e1-4425-b452-efba1522c1d5 Dimopoulos, M.A. (Meletios A.)\|\|\|/items/15a77e11-69c3-44a2-8476-eb93bbe8cc0e
author	Terpos, E. (Evangelos)\|\|\|/items/f7dbaa50-9ab3-42ba-bf5a-d80977a9f8d4
author_facet	Terpos, E. (Evangelos)\|\|\|/items/f7dbaa50-9ab3-42ba-bf5a-d80977a9f8d4 Kostopoulos, I.V. (Ioannis V.)\|\|\|/items/5854daeb-2a43-4bab-b52b-2ee713b04344 Kastritis, E. (Efstathios)\|\|\|/items/6f26f927-536f-4cab-ae12-8f9ef542619d Ntanasis-Stathopoulos, I. (Ioannis)\|\|\|/items/81f85249-34c0-4f57-99d7-80c26718f555 Migkou, M. (Magdalini)\|\|\|/items/39eca5c7-6f53-488f-a7ca-239a8d8cd00f Rousakis, P. (Pantelis)\|\|\|/items/4091ddbe-f888-4d04-beba-e7998b8ef7d7 Argyriou, A.T. (Alexandra T.)\|\|\|/items/b0888fea-4179-415e-b360-57a62744b956 Kanellias, N. (Nikolaos)\|\|\|/items/44c10986-4182-4083-b632-8d7bc7a742ee Fotiou, D. (Despina)\|\|\|/items/483113f5-569e-4a11-ae14-0fa71c306dc8 Eleutherakis-Papaiakovou, E. (Evangelos)\|\|\|/items/19bda14d-006a-4571-9066-a89417da6ef8 Gavriatopoulou, M. (Maria)\|\|\|/items/c2f76c5c-2312-417f-8ab0-b0dbe4b76f2e Ziogas, D.C. (Dimitrios C.)\|\|\|/items/7af8e18b-60c6-4f06-a041-8c544477fdda Papanota, A.M. (Aristea-Maria)\|\|\|/items/77c9cf83-fe4d-4373-bed4-fd640ebbd3f2 Spyropoulou-Vlachou, M. (Marilyn)\|\|\|/items/d94a63b1-7b9e-40f6-87ec-d899e159b37f Trougakos, I.P. (Ioannis P.)\|\|\|/items/85ec9dc3-b435-4713-ad0b-1e502f61726c Tsitsilonis, O.E. (Ourania E.)\|\|\|/items/375815ec-1178-45ab-b55a-6277eba9ddc3 Paiva, B. (Bruno)\|\|\|/items/b2c3efc5-27e1-4425-b452-efba1522c1d5 Dimopoulos, M.A. (Meletios A.)\|\|\|/items/15a77e11-69c3-44a2-8476-eb93bbe8cc0e
author_role	author
author2	Kostopoulos, I.V. (Ioannis V.)\|\|\|/items/5854daeb-2a43-4bab-b52b-2ee713b04344 Kastritis, E. (Efstathios)\|\|\|/items/6f26f927-536f-4cab-ae12-8f9ef542619d Ntanasis-Stathopoulos, I. (Ioannis)\|\|\|/items/81f85249-34c0-4f57-99d7-80c26718f555 Migkou, M. (Magdalini)\|\|\|/items/39eca5c7-6f53-488f-a7ca-239a8d8cd00f Rousakis, P. (Pantelis)\|\|\|/items/4091ddbe-f888-4d04-beba-e7998b8ef7d7 Argyriou, A.T. (Alexandra T.)\|\|\|/items/b0888fea-4179-415e-b360-57a62744b956 Kanellias, N. (Nikolaos)\|\|\|/items/44c10986-4182-4083-b632-8d7bc7a742ee Fotiou, D. (Despina)\|\|\|/items/483113f5-569e-4a11-ae14-0fa71c306dc8 Eleutherakis-Papaiakovou, E. (Evangelos)\|\|\|/items/19bda14d-006a-4571-9066-a89417da6ef8 Gavriatopoulou, M. (Maria)\|\|\|/items/c2f76c5c-2312-417f-8ab0-b0dbe4b76f2e Ziogas, D.C. (Dimitrios C.)\|\|\|/items/7af8e18b-60c6-4f06-a041-8c544477fdda Papanota, A.M. (Aristea-Maria)\|\|\|/items/77c9cf83-fe4d-4373-bed4-fd640ebbd3f2 Spyropoulou-Vlachou, M. (Marilyn)\|\|\|/items/d94a63b1-7b9e-40f6-87ec-d899e159b37f Trougakos, I.P. (Ioannis P.)\|\|\|/items/85ec9dc3-b435-4713-ad0b-1e502f61726c Tsitsilonis, O.E. (Ourania E.)\|\|\|/items/375815ec-1178-45ab-b55a-6277eba9ddc3 Paiva, B. (Bruno)\|\|\|/items/b2c3efc5-27e1-4425-b452-efba1522c1d5 Dimopoulos, M.A. (Meletios A.)\|\|\|/items/15a77e11-69c3-44a2-8476-eb93bbe8cc0e
author2_role	author author author author author author author author author author author author author author author author author
dc.contributor.none.fl_str_mv	Dadun. Depósito Académico Digital Universidad de Navarra
dc.subject.none.fl_str_mv	Minimal residual disease (MRD) Phenotypic profiles Suitable method Next-generation flow (NGF)
topic	Minimal residual disease (MRD) Phenotypic profiles Suitable method Next-generation flow (NGF)
description	Minimal residual disease (MRD) was monitored in 52 patients with sustained CR (≥2 years) after frontline therapy using next-generation flow (NGF) cytometry. 25% of patients initially MRD- reversed to MRD+. 56% of patients in sustained CR were MRD+; 45% at the level of 10−5; 17% at 10−6. All patients who relapsed during follow-up were MRD+ at the latest MRD assessment, including those with ultra-low tumor burden. MRD persistence was associated with specific phenotypic profiles: higher erythroblasts’ and tumor-associated monocytes/macrophages’ predominance in the bone marrow niche. NGF emerges as a suitable method for periodic, reproducible, highly-sensitive MRD-detection at the level of 10−6.
publishDate	2019
dc.date.none.fl_str_mv	2019 2019-01-01 2019 2019-01-01 2021 2021-10-26
dc.type.none.fl_str_mv	journal article http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv	info:eu-repo/semantics/article
format	article
dc.identifier.none.fl_str_mv	https://hdl.handle.net/10171/62276
url	https://hdl.handle.net/10171/62276
dc.language.none.fl_str_mv	Inglés eng
language_invalid_str_mv	Inglés
language	eng
dc.rights.none.fl_str_mv	open access http://purl.org/coar/access_right/c_abf2
dc.rights.openaire.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	open access http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.none.fl_str_mv	application/pdf
dc.publisher.none.fl_str_mv	Ovid Technologies (Wolters Kluwer Health)
publisher.none.fl_str_mv	Ovid Technologies (Wolters Kluwer Health)
dc.source.none.fl_str_mv	reponame:Dadun. Depósito Académico Digital de la Universidad de Navarra instname:Universidad de Navarra
instname_str	Universidad de Navarra
reponame_str	Dadun. Depósito Académico Digital de la Universidad de Navarra
collection	Dadun. Depósito Académico Digital de la Universidad de Navarra
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_	1869411559311147008
score	15,300719

Impact of minimal residual disease detection by next-generation flow cytometry in multiple myeloma patients with sustained complete remission after frontline therapy

Similares en LA Referencia